235 related articles for article (PubMed ID: 26952044)
21. Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis.
McMurtry MS; Bonnet S; Wu X; Dyck JR; Haromy A; Hashimoto K; Michelakis ED
Circ Res; 2004 Oct; 95(8):830-40. PubMed ID: 15375007
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of ubiquitin proteasome function prevents monocrotaline-induced pulmonary arterial remodeling.
Zhu Y; Wu Y; Shi W; Wang J; Yan X; Wang Q; Liu Y; Yang L; Gao L; Li M
Life Sci; 2017 Mar; 173():36-42. PubMed ID: 28212825
[TBL] [Abstract][Full Text] [Related]
23. Apoptosis-based therapy to treat pulmonary arterial hypertension.
Suzuki YJ; Ibrahim YF; Shults NV
J Rare Dis Res Treat; 2016; 1(2):17-24. PubMed ID: 27819072
[TBL] [Abstract][Full Text] [Related]
24. Ranolazine prevents INaL enhancement and blunts myocardial remodelling in a model of pulmonary hypertension.
Rocchetti M; Sala L; Rizzetto R; Staszewsky LI; Alemanni M; Zambelli V; Russo I; Barile L; Cornaghi L; Altomare C; Ronchi C; Mostacciuolo G; Lucchetti J; Gobbi M; Latini R; Zaza A
Cardiovasc Res; 2014 Oct; 104(1):37-48. PubMed ID: 25139747
[TBL] [Abstract][Full Text] [Related]
25. Inhibitory effect of calcitonin gene-related peptide on hypoxia-induced rat pulmonary artery smooth muscle cells proliferation: role of ERK1/2 and p27.
Li XW; Hu CP; Wu WH; Zhang WF; Zou XZ; Li YJ
Eur J Pharmacol; 2012 Mar; 679(1-3):117-26. PubMed ID: 22306243
[TBL] [Abstract][Full Text] [Related]
26. Characterization of carfilzomib-resistant non-small cell lung cancer cell lines.
Hanke NT; Imler E; Marron MT; Seligmann BE; Garland LL; Baker AF
J Cancer Res Clin Oncol; 2018 Jul; 144(7):1317-1327. PubMed ID: 29766327
[TBL] [Abstract][Full Text] [Related]
27. Carfilzomib inhibits the growth of lung adenocarcinoma via upregulation of Gadd45a expression.
Yang F; Liu WW; Chen H; Zhu J; Huang AH; Zhou F; Gan Y; Zhang YH; Ma L
J Zhejiang Univ Sci B; 2020 Jan.; 21(1):64-76. PubMed ID: 31898443
[TBL] [Abstract][Full Text] [Related]
28. PAR-2 inhibition reverses experimental pulmonary hypertension.
Kwapiszewska G; Markart P; Dahal BK; Kojonazarov B; Marsh LM; Schermuly RT; Taube C; Meinhardt A; Ghofrani HA; Steinhoff M; Seeger W; Preissner KT; Olschewski A; Weissmann N; Wygrecka M
Circ Res; 2012 Apr; 110(9):1179-91. PubMed ID: 22461388
[TBL] [Abstract][Full Text] [Related]
29. Intratracheal Administration of Prostacyclin Analogue-incorporated Nanoparticles Ameliorates the Development of Monocrotaline and Sugen-Hypoxia-induced Pulmonary Arterial Hypertension.
Akagi S; Nakamura K; Matsubara H; Kondo M; Miura D; Matoba T; Egashira K; Ito H
J Cardiovasc Pharmacol; 2016 Apr; 67(4):290-8. PubMed ID: 26745002
[TBL] [Abstract][Full Text] [Related]
30. Amlodipine prevents monocrotaline-induced pulmonary arterial hypertension and prolongs survival in rats independent of blood pressure lowering.
Mawatari E; Hongo M; Sakai A; Terasawa F; Takahashi M; Yazaki Y; Kinoshita O; Ikeda U
Clin Exp Pharmacol Physiol; 2007 Jul; 34(7):594-600. PubMed ID: 17581214
[TBL] [Abstract][Full Text] [Related]
31. Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells.
Nishimura T; Vaszar LT; Faul JL; Zhao G; Berry GJ; Shi L; Qiu D; Benson G; Pearl RG; Kao PN
Circulation; 2003 Sep; 108(13):1640-5. PubMed ID: 12963647
[TBL] [Abstract][Full Text] [Related]
32. Effect of Tongxinluo on pulmonary hypertension and pulmonary vascular remodeling in rats exposed to a low pressure hypoxic environment.
Wang Y; Ma TT; Gao NN; Zhou XL; Jiang H; Guo R; Jia LN; Chang H; Gao Y; Gao ZM; Pan L
J Ethnopharmacol; 2016 Dec; 194():668-673. PubMed ID: 27737815
[TBL] [Abstract][Full Text] [Related]
33. [Effects of docosahexaenoic acid on hypoxia-induced pulmonary arterial hypertension].
Chen R; Liu P; Yan J; Gu Y
Zhonghua Jie He He Hu Xi Za Zhi; 2014 Feb; 37(2):109-12. PubMed ID: 24796591
[TBL] [Abstract][Full Text] [Related]
34. A critical role for Egr-1 during vascular remodelling in pulmonary arterial hypertension.
Dickinson MG; Kowalski PS; Bartelds B; Borgdorff MA; van der Feen D; Sietsma H; Molema G; Kamps JA; Berger RM
Cardiovasc Res; 2014 Sep; 103(4):573-84. PubMed ID: 25028387
[TBL] [Abstract][Full Text] [Related]
35. Implication of PDGF signaling in cigarette smoke-induced pulmonary arterial hypertension in rat.
Xing AP; Hu XY; Shi YW; Du YC
Inhal Toxicol; 2012 Jul; 24(8):468-75. PubMed ID: 22746397
[TBL] [Abstract][Full Text] [Related]
36. Carfilzomib-induced cardiotoxicity mitigated by dexrazoxane through inhibition of hypertrophic gene expression and oxidative stress in rats.
Al-Harbi NO
Toxicol Mech Methods; 2016; 26(3):189-95. PubMed ID: 26899300
[TBL] [Abstract][Full Text] [Related]
37. Hypoxia- or PDGF-BB-dependent paxillin tyrosine phosphorylation in pulmonary hypertension is reversed by HIF-1α depletion or imatinib treatment.
Veith C; Zakrzewicz D; Dahal BK; Bálint Z; Murmann K; Wygrecka M; Seeger W; Schermuly RT; Weissmann N; Kwapiszewska G
Thromb Haemost; 2014 Dec; 112(6):1288-303. PubMed ID: 25231004
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of Notch3 prevents monocrotaline-induced pulmonary arterial hypertension.
Zhang Y; Xie X; Zhu Y; Liu L; Feng W; Pan Y; Zhai C; Ke R; Li S; Song Y; Fan Y; Fan F; Wang X; Li F; Li M
Exp Lung Res; 2015; 41(8):435-43. PubMed ID: 26317171
[TBL] [Abstract][Full Text] [Related]
39. IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies.
Bergaggio E; Riganti C; Garaffo G; Vitale N; Mereu E; Bandini C; Pellegrino E; Pullano V; Omedè P; Todoerti K; Cascione L; Audrito V; Riccio A; Rossi A; Bertoni F; Deaglio S; Neri A; Palumbo A; Piva R
Blood; 2019 Jan; 133(2):156-167. PubMed ID: 30455381
[TBL] [Abstract][Full Text] [Related]
40. Dehydroepiandrosterone: A new treatment for vascular remodeling diseases including pulmonary arterial hypertension.
Dumas de la Roque E; Savineau JP; Bonnet S
Pharmacol Ther; 2010 May; 126(2):186-99. PubMed ID: 20206649
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
